News
-
Theravance has announced that Michael W. Aguiar will replace Rick E Winningham as President and CEO effective August 15, 2014. Winningham will become CEO of Theravance Biopharma full time and will continue as Chairman of… Read more . . .
-
Aegis Therapeutics has announced the availability of “an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug.” Aegis’s intranasal product would be the only non-injectable formulation of exenatide,… Read more . . .
-
Moerae Matrix has announced the initiation of a Phase 1 clinical trial of MMI-0100, an inhaled MAPKAP Kinase 2 (MK2) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). In June 2012, the company announced… Read more . . .
-
According to OptiNose, the company has completed a Series C-1 round of financing that will support development of its second product, OPN-375 intranasal fluticasone. The company, along with partner Avanir, submitted an NDA for its… Read more . . .
-
Insmed has announced that it will move ahead with a Phase 3 trial of Arikayce inhaled liposomal amikacin for the treatment of nontuberculous mycobacteria (NTM) lung infections, with results expected in 2017. According to the… Read more . . .
-
Alexza Pharmaceuticals has announced that it will develop Staccato versions of ropinirole, a dopamine agonist, for the treatment of restless leg system (AZ-008) and for the treatment of hypomobility during OFF episodes in Parkinson’s disease… Read more . . .
-
The FDA has announced the approval of Boehringer Ingelheim’s Striverdi Respimat olodaterol SMI for the treatment of COPD. The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) recommended approval of Striverdi Respimat in January 2013. The soft… Read more . . .
-
Mystic Pharmaceuticals has announced that the United States Patent and Trade Office issued a Notice of Allowance for the company’s patent application titled “Medical Devices For Dispensing Powders” (application #13/433,586). The technology is an extension… Read more . . .
-
AstraZeneca will pay $875 million initially, plus up to an additional $1.22 billion to acquire development and commercialization rights to Almirall’s entire respiratory drug business. Almirall’s respiratory products include the Eklira/Bretaris/Tudorza aclidinium DPI, an aclidinium/formoterol… Read more . . .
-
Malvern Instruments has announced the purchase of the Archimedes particle characterization system from Affinity Biosensors after having had an exclusive distribution agreement outside of North America and a co-marketing agreement in North America for the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden